Patents-Review.com
ClassID:

116050 ⎘

C12Y207/10 - CPC Classification

Classification description:

Transferases transferring phosphorus-containing groups (2.7) Protein-tyrosine kinases (2.7.10)

Sub-classes:
Recent Application in this class:
#1
20260053803
2026-02-26

KINASE MUTANTS AND USES THEREOF

 #2
20250347696
2025-11-13

SELF-ACTIVATING FÖRSTER RESONANCE ENERGY TRANSFER (saFRET) BIOSENSORS AND METHODS FOR MAKING AND USING THEM

 #3
20250034551
2025-01-30

METHODS AND SYSTEMS FOR HIGH-THROUGHPUT BIOCHEMICAL SCREENS

 #4
20240368244
2024-11-07

CHIMERIC ENGULFMENT RECEPTOR MOLECULES

 #5
20240180965
2024-06-06

KINASE MUTANTS AND USES THEREOF

 #6
20230053231
2023-02-16

Compositions targeting the interaction domain between p27KIP1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity

 #7
20220298512
2022-09-22

SIRNA SEQUENCES TARGETING THE EXPRESSION OF HUMAN GENES JAK1 OR JAK3 FOR A THERAPEUTIC USE

 #8
20220111015
2022-04-14

TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS

 #9
20220098273
2022-03-31

Chimeric engulfment receptor molecules

 #10
20220090086
2022-03-24

IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS

 #11
20200101110
2020-04-02

Kinase mutants and uses thereof

 #12
20200055917
2020-02-20

CHIMERIC ENGULFMENT RECEPTOR MOLECULES

 #13
20190307830
2019-10-10

Compositions targeting the interaction domain between p27Kip1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity

 #14
20190292529
2019-09-26

NOVEL ISOFORM OF ANAPLASTIC LYMPHOMA KINASE AND ITS USES

 #15
20180360882
2018-12-20

Perispinal perfusion by administration of T regulatory cells alone or in combination with angiogenic cell therapies

 #16
20180311319
2018-11-01

TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS

 #17
20180299451
2018-10-18

TPM4-ALK fusion protein and composition for diagnosing cancer

 #18
20180125948
2018-05-10

Treatment of ocular neovascularization using anti-VEGF proteins

 #19
20170081412
2017-03-23

Antibody-fynomer conjugates

 #20
20170065662
2017-03-09

Compositions targeting the interaction domain between p27KiP1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity

 #21
20170057948
2017-03-02

INDOLE-LIKE TRK RECEPTOR ANTAGONISTS

 #22
20170022485
2017-01-26

Isoform of anaplastic lymphoma kinase and its uses

 #23
20160361401
2016-12-15

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS

 #24
20160332994
2016-11-17

Mutant-selective EGFR inhibitors and uses thereof

 #25
20160311780
2016-10-27

HETEROARYL COMPOUNDS AND USES THEREOF

 #26
20160137741
2016-05-19

Muscle specific tyrosine kinase-fluorophore conjugate compositions, kits and methods of using

 #27
20150250823
2015-09-10

Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour

 #28
20150030572
2015-01-29

Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders

 #29
20150025055
2015-01-22

Mutant-selective EGFR inhibitors and uses thereof

 #30
20150004101
2015-01-01

Treatment of ocular neovascularization using anti-VEGF proteins

 #31
20140371438
2014-12-18

TREATMENT OF AMD USING AAV SFLT-1

 #32
20140341977
2014-11-20

TREATMENT OF AMD USING AAV SFLT-1

 #33
20120157426
2012-06-21

Mutant-selective EGFR inhibitors and uses thereof

 #34
20110230494
2011-09-22

4,6-disubstituted pyrimidines useful as kinase inhibitors

 #35
20090137588
2009-05-28

4,6-disubstitued pyrimidines useful as kinase inhibitors